Search

everythinglearnresearchcommunity

for

Search:↓

Alopecia areata is often linked to personal or family history of allergies and autoimmune diseases.

There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.

Tofacitinib is effective and safe for treating alopecia areata.

Alopecia areata treatment should consider life quality and mental health, not just clinical results.

Alopecia Areata is a hair loss condition affecting all genders, often linked to other diseases, with treatments available but varying success rates.

Topical minoxidil can help regrow hair in alopecia areata but is less effective for severe cases.

Alopecia areata often starts before age 20, is more common in women, and may have a genetic link with other autoimmune diseases.

Diphenylcyclopropenone (DPCP) can help regrow hair in many alopecia areata patients but may cause side effects and relapses.

Topical ruxolitinib failed to regrow hair in a 66-year-old with alopecia areata.

Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.

The combination of oral PUVA and corticosteroids helps regrow hair in severe alopecia areata.

Topical DPCP is somewhat effective for hair loss in alopecia areata, but more research is needed.

Diphenylcyclopropenone (DPCP) is effective in treating alopecia areata, with most patients showing significant hair regrowth.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

Alopecia areata causes varying hair loss patterns, affecting hair, nails, and possibly glands, with treatment outcomes depending on disease duration and extent.

Some patients with severe alopecia areata developed skin darkening from their treatment, which may indicate a less effective response to the therapy.

Hispanic/Latinx patients with alopecia areata often have it before age 40, with females and certain health conditions like rheumatoid arthritis more commonly affected.

Severe alopecia areata involves higher levels of certain immune cells, which can be normalized with betamethasone.

Diphenylcyclopropenone is effective for treating alopecia areata but has a high relapse rate.

Alopecia areata is an autoimmune condition causing patchy hair loss, with treatments focusing on immune system regulation and hair regrowth.

Children with autoimmune hair loss have similar vitamin D levels to healthy kids, suggesting no extra screening is needed.

Understanding the immune-related causes of Alopecia Areata has led to potential treatments like JAK inhibitors.

Baricitinib significantly improved hair regrowth and quality of life in severe alopecia areata patients.

Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.

Alopecia areata causes patchy hair loss due to the immune system attacking hair follicles.

Baricitinib improved hair loss and arthritis in a lupus patient.

Modern treatments can effectively regrow hair and improve life for people with alopecia areata.

Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.

Tofacitinib effectively reduces hair loss in children with alopecia areata but may cause mild side effects and relapses.

Congenital alopecia areata may have genetic links and topical corticosteroids are an effective treatment.